Opportunity Information: Apply for PAR 16 121
Apply for PAR 16 121
- The HHS-NIH11 in the food and nutrition, health sector is offering a public funding opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847.
- This funding opportunity was created on Mar 09, 2016 and posted on Mar 09, 2016.
- Applicants must submit their applications by May 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)" (Funding Opportunity Number PAR 16-121) is an NIH research project grant designed to push promising basic science discoveries closer to practical therapeutic development. The central purpose of the announcement is to support early-stage preclinical studies that generate the kind of rigorous evidence needed to justify more advanced, later-phase drug or therapy discovery and development work. In other words, it focuses on turning strong biological ideas and early findings into validated leads, credible tools, and convincing datasets that can support subsequent translational steps.
This program is housed within the U.S. Department of Health and Human Services, National Institutes of Health (listed as HHS-NIH11), and is aligned with the mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The diseases and health outcomes of interest span a broad portion of NIDDKs portfolio, including obesity, diabetes, and related endocrine and metabolic disorders; digestive diseases; liver diseases; nutrition-related conditions; kidney and urological diseases; hematology; and certain specific aspects of cystic fibrosis that fall under NIDDK program priorities. The announcement points applicants to NIDDKs programmatic areas for additional context on institute priorities (via the NIDDK research programs webpage).
The funding mechanism is an R01, meaning it supports a discrete, investigator-led research project under the standard NIH grant structure. The opportunity is categorized as discretionary and sits within the health-related funding activity area (including food and nutrition and health), with CFDA number 93.847. While the source listing does not provide an award ceiling or an expected number of awards, the intent is clear: to fund research that strengthens the translational case for therapeutic leads by producing solid preclinical validation, rather than remaining at the level of purely exploratory biology.
Eligibility is broad and includes many types of organizations that commonly apply for NIH grants. Eligible applicants include public and state-controlled institutions of higher education and private institutions of higher education; nonprofit organizations both with and without 501(c)(3) status (excluding institutions of higher education in those nonprofit categories); for-profit organizations (other than small businesses) and small businesses; and multiple levels of government entities, including state, county, city or township governments, special district governments, and independent school districts. The list also includes Native American tribal governments (federally recognized) as well as Native American tribal organizations that are not federally recognized tribal governments, plus public housing authorities and Indian housing authorities. The notice also references an "Others" eligibility category with further clarification in the full announcement text.
In terms of timing, this FOA was created and posted on March 9, 2016, with the listed closing date of May 7, 2019 (shown as both the original and current closing date in the provided data). Overall, the opportunity is best understood as a translational bridge: it aims to help researchers move from compelling mechanistic insights toward credible, testable therapeutic leads for NIDDK-relevant diseases by funding the early preclinical work needed to support future development efforts.
FAQs: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01) - PAR 16-121
What is the name of this grant opportunity?
The opportunity is titled "Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR 16-121.
Which agency and department sponsor this opportunity?
This is an NIH opportunity within the U.S. Department of Health and Human Services (HHS), National Institutes of Health (listed as HHS-NIH11).
Which NIH institute is this opportunity aligned with?
The program is aligned with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
What is the main purpose of this grant?
The central purpose is to support early-stage preclinical studies that generate rigorous evidence to justify more advanced, later-phase drug or therapy discovery and development work. It is intended to push promising basic science discoveries closer to practical therapeutic development.
What kind of work is this FOA trying to fund?
It funds early-stage preclinical validation efforts that turn strong biological ideas and early findings into validated therapeutic leads, credible tools, and convincing datasets that can support subsequent translational steps.
Is this funding meant for exploratory basic science only?
No. The stated intent is to strengthen the translational case for therapeutic leads by producing solid preclinical validation, rather than remaining at the level of purely exploratory biology.
What funding mechanism does this program use?
The mechanism is an NIH R01, which supports a discrete, investigator-led research project under the standard NIH grant structure.
How is the opportunity categorized?
It is categorized as discretionary and sits within a health-related funding activity area (including food and nutrition and health).
What is the CFDA number associated with this grant?
The CFDA number listed is 93.847.
Which disease areas are within scope for this NIDDK-focused FOA?
The diseases and outcomes of interest span NIDDK mission areas, including obesity, diabetes, and related endocrine and metabolic disorders; digestive diseases; liver diseases; nutrition-related conditions; kidney and urological diseases; hematology; and certain specific aspects of cystic fibrosis that fall under NIDDK program priorities.
Does the FOA mention where to find more context on NIDDK priorities?
Yes. It points applicants to NIDDK programmatic areas for additional context on institute priorities (via the NIDDK research programs webpage).
Who is eligible to apply?
Eligibility is broad and includes multiple organization types commonly eligible for NIH grants, including higher education institutions, nonprofit organizations, for-profit organizations, small businesses, and multiple forms of government and tribal entities, plus certain housing authorities.
Are public and state-controlled institutions of higher education eligible?
Yes. Public and state-controlled institutions of higher education are listed as eligible applicants.
Are private institutions of higher education eligible?
Yes. Private institutions of higher education are listed as eligible applicants.
Are nonprofit organizations eligible?
Yes. Nonprofit organizations both with and without 501(c)(3) status are listed as eligible (excluding institutions of higher education within those nonprofit categories).
Are for-profit organizations eligible?
Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed separately as eligible.
What types of government entities are eligible to apply?
Eligible government applicants include state governments, county governments, city or township governments, special district governments, and independent school districts.
Are Native American tribal entities eligible?
Yes. Native American tribal governments (federally recognized) are listed as eligible, and Native American tribal organizations that are not federally recognized tribal governments are also included.
Are public housing authorities or Indian housing authorities eligible?
Yes. Public housing authorities and Indian housing authorities are listed among eligible applicant types.
Does the FOA include any additional eligibility category beyond the named organization types?
Yes. The notice references an "Others" eligibility category with further clarification in the full announcement text.
When was this FOA created and posted?
The FOA was created and posted on March 9, 2016.
What is the listed closing date for this opportunity?
The listed closing date is May 7, 2019 (shown as both the original and current closing date in the provided data).
Does the listing provide an award ceiling or the expected number of awards?
No. The source listing does not provide an award ceiling or an expected number of awards.
What is the overall role of this program in the research-to-therapy pipeline?
It functions as a translational bridge, aiming to move researchers from compelling mechanistic insights toward credible, testable therapeutic leads for NIDDK-relevant diseases by funding the early preclinical work needed to support future development efforts.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: Federal-State Marketing Improvement Program
Previous opportunity: Sleep and Sleep Disorders
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 121
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 121) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: Small Grant Program for NIDDK K01/K08/K23 Recipients (R03) Apply for PAR 16 148 Funding Number: PAR 16 148 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $50,000 |
| Advances in Polycystic Kidney Disease (R01) Apply for PA 16 159 Funding Number: PA 16 159 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Human Islet Distribution Coordinating Center (UC4) Apply for RFA DK 16 023 Funding Number: RFA DK 16 023 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $1,300,000 |
| Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp) Apply for PA 16 183 Funding Number: PA 16 183 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Short-Term Research Experience Program for Underrepresented Persons (STEP-UP) (R25) Apply for RFA DK 16 021 Funding Number: RFA DK 16 021 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Mentored Research Scientist Development Award (K01) Apply for PAR 16 211 Funding Number: PAR 16 211 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Nutrition Obesity Research Centers (NORCs) (P30) Apply for RFA DK 16 006 Funding Number: RFA DK 16 006 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Standardization of C-peptide and HbA1c Measurements Program (UC4) Apply for RFA DK 16 011 Funding Number: RFA DK 16 011 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $350,000 |
| Diabetes Research Centers (P30) Apply for RFA DK 16 020 Funding Number: RFA DK 16 020 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01) Apply for PAR 16 304 Funding Number: PAR 16 304 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Collaborative Islet Transplantation Registry (UC4) Apply for RFA DK 16 503 Funding Number: RFA DK 16 503 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Neurocognitive Effects of Glycemic Dysregulation in Type 1 Diabetes (DP3) Apply for RFA DK 16 007 Funding Number: RFA DK 16 007 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $3,000,000 |
| Metabolic Contributions to the Neurocognitive Complications of Diabetes: Ancillary Studies (R01) Apply for PAR 16 333 Funding Number: PAR 16 333 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Pediatric Centers of Excellence in Nephrology (P50) Apply for RFA DK 16 032 Funding Number: RFA DK 16 032 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $750,000 |
| George M. O'Brien Kidney Research Core Centers (P30) Apply for RFA DK 16 031 Funding Number: RFA DK 16 031 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $750,000 |
| Promoting Organ and Tissue Donation Among Diverse Populations (R01) Apply for RFA DK 16 022 Funding Number: RFA DK 16 022 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $150,000 |
| Limited Competition for Data Coordinating Center (DCC) for NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) (U24) Apply for RFA DK 16 510 Funding Number: RFA DK 16 510 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,062,000 |
| NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01) Apply for RFA DK 16 029 Funding Number: RFA DK 16 029 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $293,000 |
| Coordinating Unit for the Mouse Metabolic Phenotyping Centers (U24) Apply for RFA DK 16 034 Funding Number: RFA DK 16 034 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $1,212,563 |
| Coordinating Unit for Diabetic Complications Consortium (U24) Apply for RFA DK 16 036 Funding Number: RFA DK 16 036 Agency: Department of Health and Human Services, National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $3,122,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 121", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.